Cresset Asset Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Cresset Asset Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-4,000	Closed	-$226K	–	798
2020 Q3	$226K	Buy	+4,000	New	+$235K	﹤0.01%	597
2019 Q3	–	Sell	-4,000	Closed	-$214K	–	557
2019 Q2	$214K	Hold	4,000	–	–	0.01%	431
2019 Q1	$0	Buy	+4,000	New	+$211K	﹤0.01%	2076

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACM

Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

IFWM

Institute for Wealth Management Denver, Colorado $938M AUM 29.36% 1-Year Est. Return

Cresset Asset Management's PBE Position: Q4 2020 in Review

Cresset Asset Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q4 2020, closing a stake of 4,000 shares — an estimated $226K sold.

Cresset Asset Management first reported a position in PBE in Q1 2019 and held it in 3 quarters. The position peaked at $226K in Q3 2020. 81 funds tracked by Wall St. Rank hold PBE as of Q4 2020.

Cresset Asset Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q4 2020 after selling out during the quarter.
Cresset Asset Management sold 4,000 Invesco Biotechnology & Genome ETF shares in Q4 2020, an estimated $226K.
Cresset Asset Management first reported a position in Invesco Biotechnology & Genome ETF in Q1 2019 and held it in 3 quarters.
Cresset Asset Management's Invesco Biotechnology & Genome ETF position peaked at $226K in Q3 2020.
81 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2020.

Based on Cresset Asset Management's 13F filing for Q4 2020, filed 11 Feb 2021.